Steven L. Basta - 03 Jan 2023 Form 4 Insider Report for VIVEVE MEDICAL, INC.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 03 Jan 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jan 2023, 15:04:01 UTC
Prior SEC filing: 12 Aug 2022
Next SEC filing: 15 Dec 2023
Source filing: View source filing
Reporting owner signature: /s/ Jim Robbins, as Attorney-in-Fact

Key filing fact

Steven L. Basta filed Form 4 for VIVEVE MEDICAL, INC. on 05 Jan 2023.

Key facts

This page summarizes Steven L. Basta's Form 4 filing for VIVEVE MEDICAL, INC..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Jan 2023, 15:04.

Change

Previous filing in this sequence was filed on 12 Aug 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VIVE transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +72,000
Change %
Price: $0.000000
Shares after: 72,000
Date: 03 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 72,000
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock.

Footnote F2

The RSUs vest in full on the earlier of December 1, 2023 or the closing of a Sale Event (as defined in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan), subject to the reporting person's continuous service to the Issuer.